Jotin Marango Ph.D., M.D.
Net Worth
Last updated:
What is Jotin Marango Ph.D., M.D. net worth?
The estimated net worth of Dr. Jotin Marango Ph.D., M.D. is at least $3,625,646 as of 10 Jul 2020. He owns shares worth $244,397 as insider, has earned $512,949 from insider trading and has received compensation worth at least $2,868,300 in Aptose Biosciences Inc..
What is the salary of Jotin Marango Ph.D., M.D.?
Dr. Jotin Marango Ph.D., M.D. salary is $573,660 per year as Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Chief Bus. Officer in Aptose Biosciences Inc..
How old is Jotin Marango Ph.D., M.D.?
Dr. Jotin Marango Ph.D., M.D. is 46 years old, born in 1979.
What stocks does Jotin Marango Ph.D., M.D. currently own?
As insider, Dr. Jotin Marango Ph.D., M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Aptose Biosciences Inc. (APTO) | Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Chief Bus. Officer | 116,219 | $2.1 | $244,397 |
What does Aptose Biosciences Inc. do?
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Jotin Marango Ph.D., M.D. insider trading
Aptose Biosciences Inc.
Dr. Jotin Marango Ph.D., M.D. has made 2 insider trades in 2020, according to the Form 4 filled with the SEC. Most recently he sold 62,835 units of APTO stock worth $380,152 on 10 Jul 2020.
The largest trade he's ever made was exercising 62,835 units of APTO stock on 10 Jul 2020. As of 10 Jul 2020 he still owns at least 116,219 units of APTO stock.